LEVI & KORSINSKY, LLP: SECTION 10(B) AND RULE 10B-5 CLAIMS ASSERTED IN INOVIO PHARMACEUTICALS SECURITIES LITIGATION
MWN-AI** Summary
Levi & Korsinsky, LLP has initiated a securities class action against Inovio Pharmaceuticals, Inc. (NASDAQ: INO), focused on alleged violations of Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5. The lawsuit targets investors who acquired Inovio securities between October 10, 2023, and December 26, 2025, and experienced financial losses during this period.
The legal claims assert that Inovio's executives made materially false and misleading statements about the company's operations and business prospects, which concealed critical deficiencies regarding the manufacturing of its CELLECTRA device. Specifically, the complaint contends that the company did not possess the required information to justify accelerated approval eligibility and was unlikely to meet the expected timeline for submitting its Biologics License Application (BLA). Moreover, the complaint alleges that Inovio overstated the regulatory and commercial outlook for its product.
As outlined in the lawsuit, Levi & Korsinsky argues that these misleading filings directly led to substantial declines in the company’s stock price, thereby harming investors. Additionally, the complaint seeks to hold individual defendants accountable as "controlling persons" under Section 20(a) of the Exchange Act, implicating them in the dissemination of false information due to their senior roles within the company.
Joseph E. Levi, Esq., emphasizes the importance of the Private Securities Litigation Reform Act (PSLRA) in protecting affected investors. The firm, recognized for its expertise in shareholder rights, encourages individuals who believe they may qualify for participation in the lawsuit to reach out for further information. The deadline for motions for lead plaintiffs is April 7, 2026.
MWN-AI** Analysis
In light of the recent class action lawsuit filed against Inovio Pharmaceuticals, investors must approach the situation with caution. The allegations brought forth by Levi & Korsinsky, LLP under Section 10(b) and Rule 10b-5 of the Securities Exchange Act highlight potentially serious missteps by the company's management, leading to significant losses for shareholders who acquired the stock during the specified class period from October 2023 to December 2025.
The complaint alleges that Inovio executives made materially false statements about the company’s capabilities and regulatory prospects, particularly concerning the CELLECTRA device and its biologics license application (BLA). These types of claims can result in substantial volatility in stock prices, as corrective disclosures have historically correlated with sharp drops in market value.
For current shareholders, this situation presents both risks and potential opportunities. If you're holding Inovio stock, it may be prudent to monitor developments closely as legal proceedings unfold. The company’s position could be heavily influenced not only by court rulings but also by market sentiment regarding the implications of the lawsuit. Investors should consider evaluating their exposure to Inovio and weigh it against other opportunities, particularly in the biotechnology sector, which has seen fluctuations due to similar litigation risks.
For those who purchased stock during the affected timeline and suffered losses, participation in the class action may prove beneficial. Engaging with the attorneys at Levi & Korsinsky could provide a pathway to recover some losses, provided the case establishes that false or misleading statements significantly impacted stock performance.
In conclusion, while the current landscape is fraught with uncertainty, informed decision-making based on accurate, timely information will be crucial for navigating this challenging situation.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LEVI & KORSINSKY, LLP: SECTION 10(B) AND RULE 10B-5 CLAIMS ASSERTED IN INOVIO PHARMACEUTICALS SECURITIES LITIGATION
PR Newswire
Shareholders Who Purchased INO Securities During Class Period Urged to Review Options
NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP announces that a securities class action has been filed against Inovio Pharmaceuticals, Inc. (NASDAQ: INO).
YOU MAY BE AFFECTED IF YOU:
- Purchased Inovio stock between October 10, 2023 and December 26, 2025
- Lost money on your Inovio investment
- Acquired shares during the Class Period
Find out if you qualify or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-7500.
The Legal Framework Protecting Investors
Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 prohibit making untrue statements of material facts or omitting material facts necessary to make statements not misleading. The action contends that Defendants violated these provisions by making materially false and misleading statements regarding Inovio's business, operations, and prospects.
The Alleged Securities Violations
As pleaded in the complaint filed in the United States District Court for the Eastern District of Pennsylvania, Defendants allegedly failed to disclose that: (i) manufacturing for the Company's CELLECTRA device was deficient; (ii) the Company was unlikely to submit its BLA by the projected timeline; (iii) the Company had insufficient information to justify accelerated approval eligibility; and (iv) the product's regulatory and commercial prospects were overstated.
What the Complaint Allegedly Establishes
- Plaintiffs allege Defendants made false and misleading statements during the Class Period
- As pleaded, the complaint asserts violations under Section 10(b) and Rule 10b-5
- The action contends individual defendants are liable as control persons under Section 20(a)
- Plaintiffs allege Defendants violated Item 303 of SEC Regulation S-K requiring disclosure of known trends
- The complaint asserts that corrective disclosures caused significant stock price declines
Section 20(a) Control Person Claims
The complaint also asserts claims against individual defendants under Section 20(a) of the Exchange Act, alleging they acted as controlling persons of Inovio by virtue of their senior positions and ability to control the Company's public disclosures.
"The PSLRA provides important protections for investors harmed by alleged securities violations," said Joseph E. Levi, Esq. "The complaint details significant allegations about what executives knew when signing SEC filings."
Learn more about this lawsuit or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-7500.
WHY LEVI & KORSINSKY
Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors across the country. Motions for lead plaintiff must be filed with the Court by April 7, 2026.
SOURCE Levi & Korsinsky, LLP
FAQ**
What specific details regarding the allegations against Inovio Pharmaceuticals Inc. (INO) do the claims under Section 10(b) and Rule 10b-5 assert about the misrepresentation of the company’s manufacturing capabilities and regulatory prospects?
How might the outcomes of the claims asserted by Levi & Korsinsky, LLP affect the future stock price and investor sentiment regarding Inovio Pharmaceuticals Inc. (INO)?
Can you explain the significance of the alleged violations of Item 303 of SEC Regulation S-K in relation to Inovio Pharmaceuticals Inc. (INO) and how it impacts investor rights under the PSLRA?
What are the potential implications for individual defendants at Inovio Pharmaceuticals Inc. (INO) being identified as control persons under Section 20(a), and how might this influence the legal strategy of Levi & Korsinsky, LLP?
**MWN-AI FAQ is based on asking OpenAI questions about Inovio Pharmaceuticals Inc. (NASDAQ: INO).
NASDAQ: INO
INO Trading
-1.42% G/L:
$1.735 Last:
326,364 Volume:
$1.72 Open:
